4DMedical signs deal to supply lung imaging technology to Australian radiology clinics

4DMedical ASX 4DX I-MED Radiology Network lung Australia diagnostic imaging
4DMedical’s patented XV technology enables physicians to understand lung airflow and identify respiratory deficiencies with greater sensitivity and earlier than conventional methods.

Respiratory device specialist 4DMedical (ASX: 4DX) has signed a deal with I-MED Radiology Network (I-MED) to supply its industry-first lung imaging technology to more than 250 clinics throughout Australia.

The three-year agreement clears the way for 4D’s XV Technology and Lung Ventilation Analysis Software (XV LVAS) to be delivered to I-MED clinics in Sydney, Melbourne, Adelaide and Perth, allowing for widespread use by patients and their referring doctors.

4DMedical managing director and chief executive officer Dr Andreas Fouras said the landmark agreement represents a significant milestone for the company.

“Expansion of our proven capability nationwide means many more people will be able to access the latest technology in respiratory imaging,” he said.

“This deal represents a significant opportunity to drive revenue for our company [and] creates a framework for the rapid commercialisation of future 4DMedical products.”

Centre of excellence

4DMedical and I-MED have also agreed to establish a lung centre of excellence to leverage 4DMedical’s technology and expertise, and enable world-class research and development activities to advance diagnostic imaging nationwide.

Today’s deal follows the successful rollout of XV LVAS to select I-MED clinics in Victoria, Queensland, New South Wales and Tasmania Berwick.

Industry first

XV LVAS is the industry’s first and only modality which can dynamically quantify ventilation throughout the lungs, exposing patients to lower levels of radiation relative to other diagnostic methods.

It provides a state-of-the-art, non-invasive way of understanding regional lung motion and airflow, with a functionality that offers advantages when disease progression and therapeutic effectiveness need to be regularly monitored.

XV LVAS generates highly-detailed maps relating to patterns of lung motion and pulmonary function, with functional deficits detected through local (regional) differences in movement.

It allows for the detection of high and low areas of ventilation with pinpoint accuracy, with ventilation being calculated for all parts of the lung, in all phases of the breath.

    Join Small Caps News

    Get notified of the latest news, interviews and stock alerts.